ONC vs. OPTI, DEST, SBTX, OBI, NSCI, HEMO, SNG, OBD, BVX, and IMM
Should you be buying Oncimmune stock or one of its competitors? The main competitors of Oncimmune include OptiBiotix Health (OPTI), Destiny Pharma (DEST), SkinBioTherapeutics (SBTX), Ondine Biomedical (OBI), NetScientific (NSCI), Hemogenyx Pharmaceuticals (HEMO), Synairgen (SNG), Oxford BioDynamics (OBD), BiVictriX Therapeutics (BVX), and ImmuPharma (IMM). These companies are all part of the "biotechnology" industry.
Oncimmune (LON:ONC) and OptiBiotix Health (LON:OPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.
Oncimmune has higher earnings, but lower revenue than OptiBiotix Health. Oncimmune is trading at a lower price-to-earnings ratio than OptiBiotix Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncimmune's average media sentiment score of 0.26 beat OptiBiotix Health's score of 0.00 indicating that Oncimmune is being referred to more favorably in the media.
OptiBiotix Health received 77 more outperform votes than Oncimmune when rated by MarketBeat users. Likewise, 59.18% of users gave OptiBiotix Health an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
35.5% of Oncimmune shares are owned by institutional investors. Comparatively, 5.9% of OptiBiotix Health shares are owned by institutional investors. 28.8% of Oncimmune shares are owned by company insiders. Comparatively, 12.5% of OptiBiotix Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Oncimmune has a net margin of 356.25% compared to OptiBiotix Health's net margin of 0.00%. OptiBiotix Health's return on equity of -85.52% beat Oncimmune's return on equity.
Oncimmune has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, OptiBiotix Health has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
Summary
Oncimmune and OptiBiotix Health tied by winning 7 of the 14 factors compared between the two stocks.
Get Oncimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncimmune Competitors List
Related Companies and Tools
